Lora Collier, MD
Family Medicine · Locust Grove, OKNPI 1154371524
Payments from drug & device makers
Across 167 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$678
- Amgen$385
- AbbVie$275
- Novo Nordisk$225
- Bayer$206
- GSK$153
- plus $990 from 22 others
What the payments were for
- Food & beverage$2,81897%
- Education$943%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $678 |
| Amgen | 23 | $385 |
| AbbVie(2 entities) | 27 | $275 |
| Novo Nordisk | 13 | $225 |
| Bayer | 13 | $206 |
| GSK | 9 | $153 |
| Teva Pharmaceuticals USA, Inc. | 4 | $144 |
| Boehringer Ingelheim | 8 | $136 |
| Johnson & Johnson | 6 | $94 |
| Pfizer | 6 | $88 |
| Lilly USA, LLC | 5 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
| Astellas Pharma US Inc | 2 | $54 |
| Abbott | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Verona Pharma, Inc. | 2 | $29 |
| Novartis | 2 | $28 |
| Merck | 2 | $28 |
| Exact Sciences | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Alk-abello, Inc | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$123
- BEVESPI AEROSPHERE$123
- FARXIGA$123
How this compares
$2,912 in reported general payments places this provider in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 184 | $160,808 |
| MounjaroTirzepatide | 117 | $125,673 |
| JardianceEmpagliflozin | 110 | $89,967 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 100 | $79,382 |
| FarxigaDapagliflozin Propanediol | 86 | $60,616 |
| VraylarCariprazine Hcl | 39 | $58,939 |
| OzempicSemaglutide | 46 | $56,712 |
| JanuviaSitagliptin Phosphate | 35 | $39,986 |
| Repatha SureclickEvolocumab | 45 | $36,497 |
| ProliaDenosumab | 20 | $34,798 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $23,454 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $21,396 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $20,442 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $18,497 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $16,876 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $88 | $160,808184 claims |
| Lilly USA, LLCMounjaro | $86 | $125,673117 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $153 | $121,221170 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $136 | $97,421123 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $678 | $77,492109 claims |
| AbbVieVraylar | $275 | $58,93939 claims |
| Novo NordiskOzempic | $225 | $56,71246 claims |
| MerckJanuvia | $28 | $39,98635 claims |
| AmgenProlia | $385 | $34,79820 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $39 | $23,45411 claims |
| Astellas Pharma US IncMyrbetriq | $54 | $15,28830 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $61 | $11,44219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Locust Grove
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.